Imagene Advances LungOI Commercialization With New Payment Code and Pricing

Imagene, a pioneer in AI-based precision oncology, has announced significant milestones in the commercialization of its AI-based NSCLC Biomarker Profiling Test, LungOI. Earlier this year, the company secured a novel payment code and rate from the Centers for Medicare and Medicaid Services (CMS).

LungOI offers predictive analysis of NSCLC genomic alterations from H&E slides within minutes. The test, now marketed as an LDT product following its CLIA certification in Q1 2023, aims to enhance patient care by providing same-day results to physicians. These results are expected to improve the triaging process and expedite treatment decisions.

"This is a major milestone in our commercialization efforts," said Dean Bitan, Co-founder and CEO of Imagene. Dr. Ross Camidge of the University of Colorado emphasized the utility of the AI test in supporting informed clinical decisions.

Imagene is actively expanding payer coverage for LungOI and will showcase its full product line at the upcoming ASCO conference. LungOI is clinically available through Imagene's CLIA-certified lab in Arizona and can be ordered online.